Anaheim Bio is a preclinical-stage biotechnology company headquartered in Leiden, Netherlands, developing small-molecule therapeutics for calcium pyrophosphate deposition disease (CPPD), a crystal-induced inflammatory arthritis also known as pseudogout. The company was formed in 2026 from programmes spun out of Alesta Therapeutics, which was later acquired by BioMarin. Its lead program, ANA-1, is a small-molecule inhibitor designed to lower extracellular pyrophosphate (PPi), the building block of CPPD crystals, aiming to address the disease at its root cause rather than only controlling inflammation and symptoms.

CPPD is estimated to affect approximately 4% to 7% of adults in Europe and the United States, mostly people over 60, and no approved disease-modifying therapy currently exists for it. Anaheim Bio aims to become the first disease-modifying therapy for CPPD with a measurable biomarker. ANA-1 is expected to enter the clinic in 2027.

In November 2026 Anaheim Bio launched with an oversubscribed €40 million Series A financing from Droia Ventures, Frazier Life Sciences, RTW Investments, Novartis Venture Fund, RV Invest and Thuja Capital, many of them former Alesta investors. The funding is intended to take ANA-1 through IND-enabling studies and into Phase 1, with runway into 2028. The executive team includes CEO Ilan Ganot, CFO Rick Dekker, CSO Matthias Van Woensel and interim CMO Benit Maru, and the board is chaired by Luc Dochez.